Document Detail


Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation.
MedLine Citation:
PMID:  17320669     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To determine the medium term efficacy and morbidity of patients who underwent cryoablation as primary therapy for localized prostate cancer followed by a penile rehabilitation regimen. METHODS: Patients were treated with whole gland cryoablation. Those potent at intervention were encouraged to use a vacuum erection device regularly after treatment. Incontinence was defined as any leakage of urine. Potency was defined as the ability to achieve an erection sufficient to complete intercourse with or without oral pharmaceutical agents. Biochemical failure was defined as three successive rises in prostate-specific antigen, with a final value greater than 1.0 ng/mL. RESULTS: A total of 416 consecutive patients were treated. The mean patient age was 69.4 years, mean prostate-specific antigen level was 8.7 ng/mL, median Gleason score was 6, and median stage was T1c. The mean follow-up of the entire population was 20.4 +/- 14.7 months. Of those continent before treatment, 4.0% were incontinent at 6 months but only 2 (0.6%) used any absorbent pads. Kaplan-Meier analysis demonstrated progressive recovery of sexual function of preoperatively potent men, with 41.4% +/- 4.3% and 51.3% +/- 5.9% potent 1 and 4 years after treatment, respectively. No patients had rectal fistula. The actuarial probability of remaining biochemically disease free at 4 years was 79.6% +/- 2.4%, with a mean time to failure of 4.2 months. After therapy, 168 patients underwent biopsy; 17 had positive findings (10.1%). The positive biopsy rate for the entire population was 4.1% (17 of 416). CONCLUSIONS: The results of our study have indicated that cryoablation as a primary treatment of localized prostate cancer is effective with acceptable morbidity. The use of a penile rehabilitation regimen after treatment appeared to substantially increase postcryoablation potency.
Authors:
David S Ellis; Theodore B Manny; John C Rewcastle
Related Documents :
11221059 - Permanent brachytherapy: prostate seed implants as an out-patient treatment.
15368699 - Erectile dysfunction rates and requests for treatment in patients attending outpatient ...
17941029 - Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
8027619 - Pathogenesis of acute radiation injury to the rectum. a prospective study in patients.
16051949 - Identifying patients at risk for significant versus clinically insignificant postoperat...
7685429 - Laser prostatectomy performed with a right angle firing neodymium:yag laser fiber at 40...
16402199 - Lateral and posterior pillar grade changes during the treatment of perthes disease in o...
23094559 - A comparision of twin-block and forsus (frd) functional appliance--a cephalometric study.
21079159 - Neck dissection after chemoradiotherapy: timing and complications.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Urology     Volume:  69     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-26     Completed Date:  2007-03-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  306-10     Citation Subset:  IM    
Affiliation:
Urology Associates of North Texas, Arlington, Texas 76012, USA. dellis@uant.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biopsy, Needle
Combined Modality Therapy
Cryosurgery / adverse effects,  methods*
Erectile Dysfunction / etiology,  rehabilitation*
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Staging
Probability
Prospective Studies
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / mortality,  pathology*,  surgery*
Risk Assessment
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of prostate weight on operative and postoperative outcomes of robotic-assisted laparoscopic p...
Next Document:  Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate ...